openPR Logo
Press release

Biosimilar Pipeline Analysis Market Industry, Top Players by Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co.

01-14-2019 08:05 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Biosimilar Pipeline Analysis Market

Biosimilar Pipeline Analysis Market

Biosimilar is a type of biological product that is almost identical to the original product, which has undergone patent expiration. Development and validation of biosimilars are an important part of the overall production process. Regulation for biosimilar drugs plays an important role in maintaining the efficiency and balance between original and biosimilar drugs. There are various authorities such as U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), which regulate the development and commercialization of biosimilars.

Biosimilar drugs are available at relatively low prices as compared to patented drugs without compromising on efficacy.There are various patented drugs available in the market, with certain drugs such as Adalimumab, the high cost of these drugs directed the biosimilar market. There are few drugs, which are under the last phase of clinical trial are BI695502 developed by Boehringer Ingelheim, PF- 06439535 by Pfizer, Biosimilar bevacizumab by Biocon, and FKB238 by Kyowa Pharmaceutical Industry Co. Increased R&D is expected to support the growth of biosimilar pipeline analysis market.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/582

Key players of biosimilar pipeline analysis market
1 Biocon
2 Pfizer
3 F. Hoffmann-La Roche Ltd
4 Amgen
5 Kyowa Pharmaceutical Industry Co. Ltd
6 Boehringer Ingelheim GmbH
7 AstraZeneca
8 Novartis AG
9 Merck & Co

There is a need for complex infrastructure in the development of biosimilar and lengthy process of clinical trial and approval are the major challenges faced by biosimilar pipeline analysis market. Global biosimilar pipeline analysis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Europe is expected to dominate the biosimilar pipeline analysis market due to technological advancements in healthcare facilities and regulatory affiliation.

Asia Pacific is expected to closely follow Europe in terms of growth due to increased prevalence of autoimmune disease, cancer, unmet clinical needs of people, and large price conscious population of emerging economies. North America market is expected to grow significantly due to high R&D investments, which supports the growth of biosimilar pipeline analysis market in near future.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/582

Biosimilar pipeline analysis market taxonomy:

By Product Type
Human Growth Hormone
Insulin
Interferon
Peptides
Monoclonal antibodies
Others

By Services
Clinical Trials
Contract Research and Manufacturing

By Technology
Electrophoresis
Recombinant DNA Technology
Chromatography
Nuclear Magnetic Resonance Technology
Bioassay
Mass Spectrometry
Western Blotting

By Application
Oncology Disease
Auto immune Disease
Blood Disease
Growth Hormone Deficiencies

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/582

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Pipeline Analysis Market Industry, Top Players by Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co. here

News-ID: 1493608 • Views:

More Releases from Coherent Market Insights

Malt Ingredient Market Set to Boom: Strategic Insights and Growth Opportunities with Key Players Like Axereal Group, Cargill, Incorporated, RAGLETH LTD
Malt Ingredient Market Set to Boom: Strategic Insights and Growth Opportunities …
The Global Business Landscape is being reshaped by rapid innovation, rising investment and shifting regional dynamics - and at the heart of this transformation lies the Malt Ingredient Market. From 2025 to 2032, this study delivers key insights, clear segmentation and actionable intelligence to help decision-makers navigate the evolving Malt Ingredient Market and capitalise on upcoming opportunities. Report Highlights • Strategic coverage of investment hotspots, regional trend shifts and emerging segments. • Deep
Mannosylerythritol Lipids Market Poised for Strong Growth: New Report Highlights Growth Potential Through 2032
Mannosylerythritol Lipids Market Poised for Strong Growth: New Report Highlights …
The latest report by Coherent Market Insights indicates strong growth potential for the Mannosylerythritol Lipids Market from 2025 to 2032, supported by rising industry demand, expanding applications, and ongoing technological advancements. The study delivers a clear overview of market size, revenue trends, and key growth factors shaping the global landscape. This research analyzes major market drivers, restraints, challenges, and emerging opportunities, while highlighting innovation trends and financial insights influencing competitive
Asia Pacific Halal Cosmetic Market Forecast Through 2032 Highlights Emerging Trends and Strategic Growth Factors | INKIA, Martha Tilaar Group, Wipro Unza, Clara International
Asia Pacific Halal Cosmetic Market Forecast Through 2032 Highlights Emerging Tre …
The Global Business Landscape is being reshaped by rapid innovation, rising investment and shifting regional dynamics - and at the heart of this transformation lies the Asia Pacific Halal Cosmetic Market. From 2025 to 2032, this study delivers key insights, clear segmentation and actionable intelligence to help decision-makers navigate the evolving Asia Pacific Halal Cosmetic Market and capitalise on upcoming opportunities. Report Highlights • Strategic coverage of investment hotspots, regional trend shifts
Radiodermatitis Market Growth in Future Scope 2025-2032 | Acelity, Inc. (3M) BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation)
Radiodermatitis Market Growth in Future Scope 2025-2032 | Acelity, Inc. (3M) BMG …
Radiodermatitis Market is estimated to be valued at USD 442.8 Mn in 2025 and is expected to reach USD 594.6 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. The latest report by Coherent Market Insights indicates strong growth potential for the Radiodermatitis Market from 2025 to 2032, supported by rising industry demand, expanding applications, and ongoing technological advancements. The study delivers a clear

All 5 Releases


More Releases for Biosimilar

Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period View sample report https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023 The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of